On April 13, 2016, Lu, Xianping; Yu, Jindi; Yang, Qianjiao; Li, Zhibin; Pan, Desi; Shan, Song; Zhu, Jiangfei; Wang, Xianghui; Liu, Xiangheng; Ning, Zhiqiang published a patent.HPLC of Formula: 16230-24-3 The title of the patent was Preparation of pyrimidine derivatives as JAK inhibitors. And the patent contained the following:
The title pyrimidine derivatives shown in formula I [wherein, R1 is H, halogen, etc.; R2 is H, hydroxy, carboxyl, etc.; R3 is selected from H, halogen, cyano, etc.; R4 is H, C1-6 alkyl, etc.; X is NH or O] or pharmaceutically acceptable salts thereof were prepared as JAK inhibitors, and especially showed selective high inhibitory activity on JAK3. For example, compound II was prepared in a multi-step synthesis. The title pyrimidine derivatives can be used in preparing the drugs for preventing and treating the diseases related to JAK3 activity abnormality, e.g., autoimmune diseases, inflammation, cancer, proliferative diseases, bone resorption disease, organ transplant rejection, rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, psoriasis, allergic diseases, asthma, chronic obstructive pulmonary disease, leukemia or lymphoma. (assay data given). The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).HPLC of Formula: 16230-24-3
The Article related to preparation pyrimidine derivative human jak inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics